Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
Esperion (NASDAQ: ESPR) has announced it will report fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opens. Management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
The company is a commercial stage biopharmaceutical firm that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) with allosteric mechanisms.
Esperion (NASDAQ: ESPR) ha annunciato che riporterà i risultati finanziari del quarto trimestre e dell'intero anno 2024 martedì 4 marzo 2025, prima dell'apertura del mercato. La direzione ospiterà un webcast alle 8:00 ET per discutere i risultati e fornire aggiornamenti aziendali.
L'azienda è una società biofarmaceutica in fase commerciale che sviluppa e commercializza farmaci orali, approvati dalla FDA, da assumere una volta al giorno, non statinici, per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. I loro farmaci sono supportati da quasi 14.000 pazienti nel CLEAR Cardiovascular Outcomes Trial. Esperion sta inoltre sviluppando inibitori di ATP citrato liasi di nuova generazione (ACLYi) con meccanismi alosterici.
Esperion (NASDAQ: ESPR) ha anunciado que informará sobre los resultados financieros del cuarto trimestre y del año completo 2024 el martes 4 de marzo de 2025, antes de la apertura del mercado. La dirección realizará un webcast a las 8:00 a.m. ET para discutir los resultados y proporcionar actualizaciones comerciales.
La empresa es una firma biofarmacéutica en etapa comercial que desarrolla y comercializa medicamentos orales, aprobados por la FDA, de una sola dosis diaria, no estatínicos, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. Sus medicamentos están respaldados por casi 14,000 pacientes en el CLEAR Cardiovascular Outcomes Trial. Esperion también está desarrollando inhibidores de la ATP citrato liasa de nueva generación (ACLYi) con mecanismos alostéricos.
Esperion (NASDAQ: ESPR)은 2025년 3월 4일 화요일, 시장 개장 전에 2024년 4분기 및 연간 재무 결과를 보고할 것이라고 발표했습니다. 경영진은 결과를 논의하고 사업 업데이트를 제공하기 위해 오전 8:00 ET에 웹캐스트를 개최할 예정입니다.
이 회사는 심혈관 질환 및 높은 LDL-C 수치를 가진 환자를 위한 FDA 승인 경구용 비스타틴 약물을 개발하고 상용화하는 상업 단계의 생명공학 회사입니다. 그들의 약물은 거의 14,000명의 환자가 참여한 CLEAR Cardiovascular Outcomes Trial에 의해 지원됩니다. Esperion은 또한 알로스테릭 메커니즘을 가진 차세대 ATP 시트레이트 리아제 억제제(ACLYi)를 개발하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé qu'il publiera les résultats financiers du quatrième trimestre et de l'année complète 2024 le mardi 4 mars 2025, avant l'ouverture du marché. La direction animera un webcast à 8h00 ET pour discuter des résultats et fournir des mises à jour sur l'entreprise.
L'entreprise est une société biopharmaceutique en phase commerciale qui développe et commercialise des médicaments oraux, approuvés par la FDA, à prendre une fois par jour, non statiniques, pour les patients atteints de maladies cardiovasculaires et ayant des niveaux élevés de LDL-C. Leurs médicaments sont soutenus par près de 14 000 patients dans l'essai CLEAR Cardiovascular Outcomes. Esperion développe également des inhibiteurs de l'ATP citrate lyase de nouvelle génération (ACLYi) avec des mécanismes allostériques.
Esperion (NASDAQ: ESPR) hat angekündigt, dass die finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Dienstag, den 4. März 2025, vor Markteröffnung veröffentlicht werden. Das Management wird um 8:00 Uhr ET ein Webcast veranstalten, um die Ergebnisse zu besprechen und Unternehmensupdates zu geben.
Das Unternehmen ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das orale, einmal täglich einzunehmende, von der FDA zugelassene Medikamente ohne Statine für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C entwickelt und vermarktet. Ihre Medikamente werden durch die fast 14.000 Patienten umfassende CLEAR Cardiovascular Outcomes Trial unterstützt. Esperion entwickelt auch Inhibitoren der ATP-Citratlyase der nächsten Generation (ACLYi) mit allosterischen Mechanismen.
- FDA-approved oral medications in commercial stage
- Large-scale validation through 14,000 patient CLEAR trial
- Development of next-generation ACLYi program
- None.
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates.
A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When will Esperion (ESPR) report Q4 and full year 2024 financial results?
What time is Esperion's (ESPR) Q4 2024 earnings webcast?
How long will Esperion's (ESPR) Q4 2024 earnings webcast replay be available?
What is Esperion's (ESPR) main commercial product focus?
How many patients were involved in Esperion's (ESPR) CLEAR Cardiovascular Outcomes Trial?
